Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 8/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3386405 | 0.84 | REN (0.43) | CTSSRENBCHEACHE | |
| SCHEMBL3386397 | 0.84 | REN (0.43) | CTSSRENBCHEACHE | |
| SCHEMBL3386550 | 0.81 | CYP1A2 (0.46) | CTSSCTSKHDAC4HDAC1HDAC6 | |
| SCHEMBL3386548 | 0.81 | CYP1A2 (0.46) | CTSSCTSKHDAC4HDAC1HDAC6 | |
| SCHEMBL3386554 | 0.81 | CYP1A2 (0.46) | CTSSCTSKHDAC4HDAC1HDAC6 | |
| SCHEMBL3383794 | 0.78 | HDAC4 (0.39) | CTSSCTSKHDAC4HDAC1HDAC6 | |
| SCHEMBL3382009 | 0.76 | CYP1A2 (0.41) | CYP1A2CYP3A4METAP2BCHE | |
| SCHEMBL82825 | 0.76 | CYP1A2 (0.41) | CYP1A2CYP3A4METAP2BCHE | |
| SCHEMBL3381445 | 0.69 | CYP1A2 (0.45) | CYP1A2CYP3A4RENMETAP2BCHE | |
| SCHEMBL7500845 | 0.69 | CYP1A2 (0.45) | CYP1A2CYP3A4RENMETAP2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828974-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20120208784-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8183231-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-1765850-B1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMA INC (US) | 2010-12-01 | — | — | EP | disclosed |
| EP-1765850-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | Aventis Pharmaceuticals, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20070060502-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | disclosed |
| WO-2005118618-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060502-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | PHOSPHO1, PTEN, PLCB1 | CTSS 3048/4885CTSK 3939/4885HDAC4 4455/4885 |
| US-20120208784-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | PHOSPHO1, PTEN, PLCB1 | CTSS 3048/4885CTSK 3939/4885HDAC4 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.